ArticleJAMA network open2022

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Jee H Choe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.